Differential Expression of Glucokinase activity in Indian Type-2 Diabetes...

[Full title: Differential Expression of Glucokinase activity in Indian Type-2 Diabetes Patients]

Life International Journal of Pharmacology ISSN 1811-7775 Life science alert ansinet Asian Network for Scientific Information

International Journal of Pharmacology 6 (4): 500-504, 2010 ISSN 1811-7775 2010 Asian Network for Scientific Information Differential Expression of Glucokinase activity in Indian Type-2 Diabetes Patients *P. Shankaraiah, 'Y. Narsimha Reddy, A. Venkatesham, N. Venkata Rajaiah and D.R. Krishna 'Department of Pharmacology and Clinical Pharmacy, Kakatiya University, Warangal, India 'Department of General Medicine, MGM, Warangal, India Abstract: Glucokinase (GK) is a type IV isoenzyme that belongs to the family of hexokinases. CK plays a role in the glucose metabolism of the liver and a glucose sensor in pancreatic SS-cells involved in glucose-dependent. insulin release Therefore we estimated the glucokinase levels in Indian type 2 diabetic populations. Selection of the study group was as follows: (1) Twenty nondiabetic subjects (control group), (2) thirty newly detected diabetic patients (without realment). (3) forty three diabetic patients on combination frealment. (4) thirty diabetic patients on pioglitazone alone treated. In all the subjects Anti diabetic activity criterion was taken for the diagnosis. In the same subjects fasting and post-prandial GK enzyme levels were estimated. Fasting and post-prandial Glucokinase levels in different groups were statistically significant, except between the non diabetic vs. anti diabetic drug treated group. It showed significant p-value regarding fasting and post-prandial glucokinase levels. Glucokinase levels in oral antidiabetic (combination) drugs (4.3–1.4 and 5.8±1.1 UL¯) and pioglitazone alone treated groups showed significantly higher (3.81 0.9 and 5.1 0.7 U L ) than newly diagnosed type-2 diabetic patients (3.5=1.1 and 1.7=0.7 UL-¹) in fasting and post-prandial condition. Fasting and post-prandial glucokinase levels were low in newly detected, raised in drug-treated diabetic subjects and varied significantly increased in treated diabetic group. This change may be attributed to chronicity of diabetes due to effect of pioglitazone on post-prandial Glucokinase levels. Key words: Clucokinase, pioglitazone, type-2 diabetes, Indian patients INTRODUCTION Glucokinase (GK) is a type IV isoenzyme that belongs to the family of hexokinases (ATP: D-hexose 6phosphotransferase; EC 2.7.1.1) and catalyzes the formation of glucose 6 phosphate in cukaryotic cells. (Dipietro et al., 1962; Vinuela et al., 1963) has a molecular mass of 52 kDa and a low affinity for glucose and is not subject to feedback inhibition by glucose 6phosphate. The GK activity is expressed in liver (Printz et al., 1993), the pancreatic islets of Langerhans (Matschinsky and Elleman, 1968), jejunal enterocytes. euroendocrine cells and brain (Jetton et al., 1994; Navamo et al., 1996; Roncero et al., 2000), GK plays a role as a beta cell glucose sensor by integrating blood glucose levels and glucose metabolism with insulin secretion (Matschinsky. 1990; Zelent et al., 2005; Matschinsky. 2000) and facilitative glucose transporter GLUT2 (Thiel et al., 2003) present in SS-cells and hepatocytes. extracellular glucose concentrations are sensed intracellularly by GK (Richter, 1992), which determines the threshold for insulin secretion, whereas in the liver, GK facilitates hepatic glucose uptake during hyperglycemia (Cronstein, 1985). The GK has a major role in the control of blood glucose homeostasis because it is the predominant hexokinase expressed in the liver, has very high control strength on hepatic glucose disposal (Dipietro et al., 1962) and is the glucose sensor for insulin secretion in pancreatic Beta-cells (Agius, 2008). Glucokinase is currently considered a strong candidate target for antihyperglycemic drugs for type 2 diabetes (Matschinsky et al., 2006; Coghlan and Leighton, 2008; Agius, 2007). This is supported by the impact of mutations in the glucokinase gene on blood glucose concentration in humans. Inactivating mutations that. lower the enzyme affinity for glucose or compromise glucokinase expression cause diabetes (maturity onset diabetes of the young lype 2). Type 2 diabetes is associated with defective regulation of hepatic glucose metabolism and impaired conversion of glucose to glycogen (Basu et al., 2000; Krssak et al., 2004). This described as decreased autoregulation or glucose effectiveness (Mevorach el al., 1998). Hepulic glucokinase activity was shown to be either elevated in newly diagnosed type 2 diabetic patients (Van Schallingen et al., 1997) or decreased in obese subjects with diabetes (Shin et al., 2007). Hepatic glucokinase is regulated by an inhibitory protein Corresponding Author: Dr. Y. Narsimha Reddy, Department of Pharmacology and Clinical Pharmacy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal-506 009, AP, India 500

Int. J. Pharmacol., 6 (4): 500-504, 2010 glucokinase regulatory protein (GKRP) that binds glucokinase with high affinity at basal glucose concentrations (5 mmol L-) and sequesters glucokinase in the nucleus in an inactive sale (Agius, 2008; Payne et al, 2007). In the postprandial state, hyperglycemia causes dissociation of glucokinase from GKRP and translocation to the cytoplasm. It could be speculated that decreased glucose effectiveness in type 2 diabetes in humans may involve decreased glucokinase expression or impaired regulation by GKRP. as occurs in animal models of insulin resistance (O'Doherty et al., 1999; Postic et al., 2001) in addition to other metabolic defects. For hepatic glucokinase to be an effective target for antihyperglycemic drugs (GKAS) in type 2 diabetes in humans, there are must be sufficient. expression of endogenous glucokinase can elicit a substantial increment in glucose phosphorylating capacity. Glucose disposal in the dysregulated diabetic state and important criterion is that glucokinase activation in diabetes that would further aggravates hepatic insulin resistance (Torres et al., 2009). There are no clinical data on both phenotypic or genotypic glucokinase expression and polymorphism of glucokinase in Indian type-2 diabetic patients. Therefore, we determined to study the glucokinase levels in fasting/post-prandial states in different groups of subjects. MATERIALS AND METHODS Glucokinase (enzyme) from Sigma, St. Louis, MO, USA. This HCL, G6PD, ATP, NAD and D-Glucose were from IIi-Media Ltd., Mumbai, India. Glucose kit was from Excel Diagnostics, Hyderabad, India. Metformin and pioglitazone combination tablets were from Medibast Pharma Ltd., Chennai, India. Pioglitazone tablets were from Kare labs Pvt. Ltd., Goa. Study design: Group 1: Twenty non-diabetic subjects (control) Group 2: Thirty newly diagnosed type 2 diabetes without treatment Group 3: Forty three diabetic patients on oral antidiabetic drug treatment (metformin and Pioglitazone combination) for more than 6 months Group 4: Thirty diabetic patients on oral antidiabetic drug treatment (Pioglitazone alone) for more than 6 months alone All patients were recruited at the department of general medicine, Mahatma Gandhi memorial Hospital. Warangal andhra Pradesh, India from March 2008 to April 2009. All subjects were attending general health check up at our outpatient department (Thursday-Diabetic Care Programme) in MGM Hospital. Subjects were excluded if they had chronic gastrointestinal diseases associated with chronic pancreatitis, history of any malignant disease, history of alcohol abuse, kidney or liver failure and other diseases affecting carbohydrate metabolism. Fasting as well as post-prandial blood samples were collected from all subjects and fasting and post-prandial serum glucose and Glucokinase levels were estimated. Serum glucose levels were estimated by glucose oxidase/peroxidase (GOD/POD) method (Trinder, 1969). Different concentrations of Glucokinase (0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 L) in were prepared for calibration curve. Glucokinase activity was measured by a colorimetric assay (Goward, 1986). The study was approved by institutional ethics committee (Kakatiya Medical College, Warangal) and informed consent was obtained from each subject according to the principles of the declaration of Helsinki. serum Statistical analysis: All variables are expressed as Mean SD. Group differences of continuous variables were compared using ANOVA followed by Student-Newman Keuls post hoc test. For all analyses, a p-value 0.05 was considered to be statistically significant.. All analyses were performed using INSTAT 1.12 (Graph-Pad Software, Inc., San Diego, CA). RESULTS Glucokinase levels in fasting/postprandial states in different groups were compared (nondiabetic, newly detected and anti diabetic drug treated. Table 1 shows the clinical characteristics of all group subjects Glucokinase levels in oral antidiabetic (combination) drugs (4.3±1.4 and 5.8 1.1 L. and pioglitazone alone treated groups showed significantly higher (3.84-0.9 and 5.1-0.7 UL-) than newly diagnosed type-2 diabetic patients (3.5±1.1 and 1.7+07 UL) in fasting condition Statistical significant levels of Glucokinase in different groups represented in Table 2. Ratio of fasting/post-prandial Glucokinase is <1 in normal controls and newly detected diabetics without treatment, but the same ratio is noted >1 in chronic drug-treated group The results of present study indicate that fasting Glucokinase levels in different groups were statistically significant (p<0.05). Similarly post-prandial Glucokinase levels in different groups were statistically significant (p<0.05), except between the nondiabetic vs. anti-diabetic drug treated group. 501

Int. J. Pharmacol., 6 (4): 500-504, 2010 Table 1: Clinical characteristics of subjects participating in the study Parameter Age (years) Sex (M/F) BMI (kg Fasting glucose (mg %) Post-prandial glucose (mg %) Non diabetic 25.85±2.4 20(12/08) 21.5±2.3 76.8±11.4 104.5±11.1 Newly-detected 48.12±12.1 30(18/12) 26.3±3.3 169.3±23.4 243.6±29.5 Oral antidiabetic (combination) 49.9±10.6 43(25/18) 24.4±2.3 Fasting glucokinase (UL-¹) post prandial glucokinase (UL) 4.6±1.00 6.2±1.6 3.5±1.1 1.72±0.7 Table 2: Statistical significance levels of GK activity in different groups Postprandial <0.005 <0.021 p-valuc Glucokinase activity Fasting Non-diabetic vs. newly detected <0.001 Non-diabetic vs. anti-diabetic <0.005 (combination) treated Anti-diabetic (combination) <0.001 <0.001 treated vs. newly detected Pioglitazone treated vs. newly detected <0.005 Pioglitazone treated vs. non diabetics Pioglitazone treated vs. anti-diab clic (combination) <0.001 <0.052 NS NS NS Values were expressed as Mean±SD. The p-value less than 0.05 are considered as statistically significant. NS: Non significant DISCUSSION In comparison to non-diabetic group (4.6 1.0) fasting Glucokinase levels in newly detected diabetics (3.5+1.1) are significantly decreased and moderately raised in combination and pioglitazone treated (4.3 1.3 and 3.8 1.0 UL¹). Regarding post-prandial Glucokinase, significantly decreased in newly detected group (1.7±0.22) but much elevated in combination treated and pioglitazone (5.8±0.8 and 5.1±0.7 UL). Table 2 shows fasting Glucokinase levels were statistically increased in all the groups. Postprandial Glucokinase levels were also significantly decreased in all the groups except. non-diabetic vs combination treated and pioglitazone but when compared to normal and treated uncontrolled group, significant p values were observed in treated group. Oric interesting observation is that, post-prandial Glucokinase levels were decreased in comparison to fasting Glucokinase levels, in newly detected group but not decreased. The thiazolidinediones, synthetic ligands of Peroxisomal Proliferator-Activated Receptor-gamma (PPAR-gamma) improve peripheral insulin sensitivity and glucose-stimulated insulin secretion in pancreatic beta-cells. To explore the role of PPAR-gamma in glucose sensing of beta-cells, we have dissected the beta-cellspecific glucokinase (GK) promoter, which constitutes glucose-sensing apparatus in pancreatic beta-cells and identified a Peroxisomal Proliferator Response Element (PPRE) in the promoter (Kim et al., 2002) and other reports are thiazolidinediones (TZDs), synthetic ligands of Peroxisome Proliferator-Activated Receptor (PPAR)-Y, are known decrease hepatic glucose production and 95.1±25.4 124.6±20.5 4.3±1.4 5.8±1.1 Pioglitazone treated 48.12-12.1 30(18/12) 26.3±3.3 107.8 18.5 131.3=22.7 3.8±0.9 5.1±0.7 increase glycogen synthesis in diabetic animals. Recently it was reported that glucokinase (GK) expression was increased by TZDs in the liver of diabetic ZDF rats (Kim et al., 2004). The concept of combination therapy for type 2 diabetes has been widely explored with drugs that target different organs such as insulin secretagogues and insulin sensitizers or metformin. The combined effects of up regulation of glucokinase and down regulation of phosphorylase-a on hepatocyte glycogen metabolism because both enzymes have a high control strength on glycogen metabolism (Agius et al., 1996; Aiston et al., 2001) and both glucokinase activators (Grimsby et al., 2003). In animal studies, it has been shown that chronic hyperglycemia decreases glucokinase activity and that restoration of euglycemia results in the normalization of Glucokinase activity (Nawano et al., 2000). Nonetheless, the fractional inactivation of phosphorylase is modest. compared with the increase in glycogen synthesis. Stimulation of glucokinase translocation by insulin (Agius and Peak, 1993), these observations may be due to chronicity of diabetes mellitus or with pioglitazone treatment or uncontrolled metabolic status in spite of Glucokinase being high Low levels of Glucokinase (fasting and post-prandial) in early stage of Diabetic Mellitus (newly detected) show a reactive phase in the evolution of diabetes mellitus. This reactive phase is whether due to decreased in the early onset of diabetes is unknown. CONCLUSIONS Indian ethnic groups show decreased post-prandial response of Glucokinase in newly detected diabetic group without treatment. Fasting Glucokinase levels show negative correlation with duration of diabetes. But post-prandial Glucokinase levels are significantly lower in newly detected group when compared to normal controls. This is a contradictory finding to the conclusion. The present study results. indicates that the scrum Glucokinase activity in patients with type-2 diabetes mellitus correlates negativity with blood glucose levels. but is not acutely affected by food intake. This special reactive phase is seen in Indian ethnic groups. Further studies are required in this line. Reversal of fasting/post- 502

Int. J. Pharmacol., 6 (4): 500-504, 2010 randial Glucokinase ratio in the course of diabetes mellitus can be taken as a parameter for therapeutic intervention either by multiple drugs or insulin. This reversal of ratio. might also be revealing failure of other response. ACKNOWLEDGMENTS The first author is thankful to University grants commission (UGC), New Delhi, India for providing Rajiv Gandhi National Junior Research Fellowship. REFERENCES Agius, L. and M. Peak, 1993. Intracellular binding of glucokinase in hepatocytes and Iranslocation by glucose, fructose and insulin. Biochem. J., 296: 785-796. Agius, L., M. Peak, C.B. Newgard, A.M. Gomez-Foix and J.J. Guinovart, 1996. Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis. J. Biol. Chem.. 271: 30479-30486. Agius, L., 2007. New hepatic targets for glycaemic control in diabetes. Pract. Res. Clin. Endocrinol. Metab. 21 587-605. Agius, L., 2008. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem. J., 414: 1-18. Aistori, S., L. Hampson, A.M. Gómez-Foix, J.J. Guinovart. and L. Agius, 2001. Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: Evidence from metabolic control analysis. J. Biol. Chem., 276: 23858-23866. Basu, A. R. Basu, P. Shah, A. Vella and C.M. Johnson et al., 2000. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes, 49: 272-283. Coghlan, M. and B. Leighton, 2008. Glucokinase activators in diabetes management. Expert Opin. Investig. Dngs, 17: 145-167. Cronstein B.N., E.D. Rosenstein, S.B. Kramer, G. Weissmann and R. Hirschhorn, 1985. Adenosine, a physiologic modulator of superoxide anion generation by human neutrophils: Adenosine acts via an A2 receptor on human neutrophils. J. Immunol... 2: 1366-1371. Dipietro, D.L., C. Sharma and S. Weinhouse, 1962. Studies glucose phosphorylation rat liver. on Biochemistry, 1: 155-162. rwn Goward, C.R., 1986. Enzymatic assay of gucokinase. Biochem. J., 237: 415-420. Grimsby, J., R. Sarabu, W.L. Corbett, N.E. Haynes and F.T. Bizzaro et al., 2003. Allosteric activators of glucokinase Potential role in diabetes therapy. Science, 301 370-373. Jetton, T.L., Y. Liang, C.C. Pellepher, E.C. Zimmerman and F.G. Cox et al., 1994. Analysis of upstream glucokinase promoter activity in transgenic mice and identificationI of glucokinase Ticuroendocrine cells in the brain and gul. J. Biol. Chem, 269: 3641-3654. nzn tage Kim, H.I., J. Y. Cha, S. Y. Kim, J.W. Kim and K.J. Rohet al. 2002. Peroxisomal proliferator gamma-activated receptor-upregulates glucokinase gene expression in beta-cells. Diabetes, 51: 676-685. Kim, S.Y., H.I. Kim, S.K. Park, S.S. Im, T. Li, H.G. Cheon and Y.H. Ahn, 2004. Liver glucokinase can be activated by peroxisome proliferator-activated receptor-y. Diabetes, 53: 866-870. Krssak, M., A. Brehm, E. Bernroider, C. Anderwald and P. Nowotny et al., 2004. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes, 53: 3018-3056. Matschinsky, F.M. and J.E. Ellerman, 1968. Metabolism of glucose in the islets of Langerhans. J. Biol. Chem., 2413: 2730-2736. Matschinsky, F.M., 1990. Glucokinase as glucose sensor and metabolic signal generator in pancreatic betacells and hepatocytes. Diabetes, 39: 617-652. Matschinsky, F.M., 2000. Glucokinase, glucose homeostasis and diabetes mellitus. Curr. Diab. Rep.. 55: 171-176. Malschinsky, F.M., M.A. Magnuson, D. Zelenl T.L. Jellon and N. Doliba et al., 2006. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes, 55: 1-12. Mevorach, M., A. Giacca, Y. Aharon, M. Hawkins, H. Shamoon and .. Rossetti, 1998. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J. Clin. Invest.. 102: 744-753. Navarro, M., F. Rodriquez de Fonseca, E. Alvarez, J.A. Chowen and J.A. Zueco et al., 1996. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2 and glucokinase mRNAs in rat hypothalamic cells: Evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J. Neurochem., 67: 1982-1991. Nawano, M., A. Oku, K. Leta, I. Umebayashi and T. Ishirahara et al., 2000. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am. J. Physiol. Endocrinol. Metab., 278: E535-E543. 503

Int. J. Pharmacol., 6 (4): 500-504, 2010 O'Doherty, R.M., D.L. Lehman, S. Telemaque-Potts and C.B. Newgard, 1999. Metabolic impact of glucokinase overexpression in liver. Lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes, 48: 2022-2027. and Payne, V.A., C. Arden, A.J. Lange and L. Agius, 2007. Contributions of glucokinase phosphofructokinase-2/fructose bisphosphatase-2 to the elevated glycolysis in hepatocytes from Zucker fa/fa rats. Am. J. Physiol Regul Integr. Comp. Physiol., 293: R618-R625. Postic, C., M. Shiola and M.A. Magnuson, 2001. Cellspecific roles of glucokinase in glucose homeostasis. Recent Prog. Horm. Res., 56: 195-217. Printz, R.L., M.A. Magnuson and D.K. Grammer, 1993. Mammalian glucokinase. Ann. Rev. Nutr., 13: 163-196. Richter, J. 1992. Effect of adenosine analogues and CAMP-raising agents on TNF, GM-CSF-and chemotactic peptide-induced degranulation in single adherent neutrophils. J. Leukoe. Biol., 51: 270-275. Roncero, I., E. Alvarez, P. Vazquez and E. Blazquez, 2000. Functional glucokinase isoforms are expressed in rat Brain. J. Neurochem., 74: 1848-1857. Shin, J.S., T.P. Torres, R.L. Catlin, D.P. Donahue and M. Shiota. 2007. A defect in glucose-induced dissociation of glucokinase from the regulatory protein in Zucker diabetic fatty rats in the early stage of diabetes. Am. J. Physiol. Regul. Integr. Comp. Physiol., 292: R1381-R1390. Thiel, M., C.C. Caldwell and M.V. Sitkovsky, 2003. The critical role of adenosine A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect. 5: 515-526. Torres, T.P., R.L. Catlin, R. Chan, Y. Fuijimoto and N. Susaki et al., 2009. Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats. Diabetes, 58: 78-86. Trinder, P., 1969. Determination of blood glucose using an oxidaseperoxidase system with a non-carcinogenic chemogen. J. Clin. Pathol., 22: 158-161. Van Schaftingen, E., M. Veiga-da-Cunha and L. Niculescu. 1997. The regulatory protein of glucokinase. Biochem. Soc. Trans., 25: 136-140. Vinuela, E., M. Salas and A. Sols, 1963. Glucokinase and hexokinase in liver in relation to glycogen synthesis. J. Biol. Chem., 238: 1175-1177. Zelent, D., H. Najali and S. Odili, 2005. Glucokinase and glucose homeostasis: Proven concepts and new ideas. Biochem. Soc. Trans., 33: 306-310. 504